2025-09-25: DEUSG Virtual

Opening

3 min

Shane Byrnes

Welcome & reminder to start recording

Analysis of Less Granular Clinical Drug

20 min

Guillermo Reynoso

Feedback to the group on analysis of c.600 Clinical Drugs looking at less granular modelling

Notes:

• Less Granular alternatives: Active ingredient CDs, BoSS CDs, Base CDs.

  • Other options: Dose forms (grouped)

Pharmaceutical / biologic product hierarchy

10 min

Dion McMurtrie / Matt Cordell

Question to the group.

Are members using the top level children of the pharmaceutical / biologic product hierarchy for drug extensions? If so, how?

Open

Open Discussions

10 min

Shane / All

Highlighting some open discussions on SNOMED Forums:

• Concept Specificity in 'Extract' Substances (e.g. plant extracts)

• Strength Numerators in Gaseous Medicinal Products Discussed at International Editors' meeting 23rd September meeting - Jim Case advised if no change in meaning then inactivation not necessary.

Topics for Antwerp

5 min

All

Any member proposals for Antwerp topics.

AOB

5 min

All

Topic Backlog

• Substances Co-ordination (MF/2025 Priority topic)

  • Step 1: Substances in multiple extensions Complete

  • Step 2: Substances in one extension. Underway

  • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)

• Medication Stopped v Medication Discontinued (Karen, SI)

• Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work + ES)

• Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 

• Increase range of has active ingredient to include microorganisms and natural products (Guillermo, CA, AU)

• Link between Substances and the organism they come from (Cat dander protein → Cat organism) see PCP-6

• Rounding rules - update on where SI is at with current guidance (Linda, CA)

• Adding |Dose form after transformation| to the Dose form concept model (Linda, CA)

Done or in progress:

• Less Granular Clinical Drug Group discussions underway on potential options for modelling

• Elemental Substances (Matt, AUS) Presentation on challenges shared. For consideration

• Units of Measure - proposal for rationalisation of concepts (Emma, UK) Briefing Note drafted

• Hydration Subsumption 'Option 3' proposed by DEUSG for communication/consultation with MAG and EAG

• Group Input on Patch Strength Representation Briefing note now being implemented

• Dose Form Intended Site v Route of Administration (BEL) Pending implementation use-cases associated with intended site

• Drug extension MRCM attributes (CA, AUS) SI facilitating links with CA and AUS for cross-promotion, next steps: other countries to be invited to add to catalogue

• Value range of a |Has container type| attribute (Linda, CA)

• Routes of Administration - Implementation Considerations (Mia, NZ)